According to Acumen Research and Consulting, the global Nebulizer market is expected to grow at noteworthy CAGR around 6.2 % throughout the forecast period and reach around US$ 1.4 billion by 2026.
Nebulizer is a medical device that converts the medicine into a nebula and directly into the pulmonary system. Nebulization techniques are commonly used to treat breathing conditions such as asthma, cystic fibrosis, and COPD. Different nebulization devices are used. The most commonly used devices are rechargeable and electrically powered. During the forecast period, the global nebuliser market will increase with moderate CAGR. The prevalence of breathing conditions combined with an aged population is fueling the growth of the global market for nebulization. The use of mobile nebulizers also drives the market. As nebulization is a spraying technology, dispersal and waste of the medication is the main constraint for the growth of the market during delivery into the respiratory tract. Further growth is also impaired by the availability of nebulizer substitutes. The promising growth opportunities for this market are provided by emerging economies like the Asia / Pacific.
The report provides analysis of global Nebulizer market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
Some of the major growth drivers include the high prevalence of chronic respiratory conditions, the growing demand for home healthcare, and the growing global geriatric population. Progress in technology is anticipated to fuel growth further.
One of the main drivers of market growth is the high prevalence of chronic diseases. According to the Global Burden of Disease Study, for example, in 2016 there was an estimated 251 million people worldwide suffering from CPD. In 2015, around 3.17 million deaths were reported due to COPD, according to the World Health Organization (WHO).
Initiatives such as the Global Appeal Alliance are likely to raise the rate and diagnosis of respiratory disorders, which can boost the market for nebulizers. Furthermore, according to the 2015 WHO report, 16 million people die each year before 70 years of age from non-communicable diseases.
In addition, the increased prevalence of respiratory disorders may also result in factors, such as obesity, unhealthy eating habits, a lack of physical activity and overconsumption of tobacco / alcohol. Over the forecast period this factor can contribute to market growth.
Based on the type, pneumatic, mesh and ultrasound nebulizers are transformed into. The segments of the pneumatic and ultrasonic nebulizers are segmented into independent and portable segments. Due to the high prevalence of respiratory disorders among the aging population, pneumatic nebulizers held a dominant share in 2018.
The segment of mesh nebulizer is expected to experience the rapid growth over the forecast period. These can be both static and vibrating. Static mesh nebulizers use a force on the liquid drug for pushing it into a static mesh, while mesh vibration or deformation in vibrating mesh nebulizers is used to push the liquid into the mesh. Omron Corporation's MicroAIR U100s, Schuco S5000s of Allied Healthcare and Philips Healthcare's Aeroneb Go are some of the products offered by the main players on the market.
Due to the increasing incidence of chronic respiratory diseases, North America accounted for the largest part of the market in 2018 and has been estimated to see significant growth during the forecast period. COPD has been estimated to be the third leading cause of death in the USA in 2014 under the Centers of Disease Control and Prevention (CDC). In addition, increased geriatric population in North America results in an increasing number of respiratory disorders and operations that will also increase regional growth. Approximately 16.1% of the population were aged 65 and over in July 2015, according to Statistics Canada. The number of homecare services has increased, creating a favorable growth environment.
During the forecasted period as a result of increasing geriatric population and respiratory disease cases, Asia Pacific Region will be expected to present the fastest CAGR. According to the Japanese Ministry of Health, Labor and Welfare, COPD is the seventh most frequent cause of death in Japan. Moreover, in Japan cases of COPD increased 24.2 percent from 2005 to 2016, according to the Institute for Health Metrics and Evaluation. In addition, the pulmonary diseases are estimated to have a significant proportion of population in countries like India and China. The WHO says that around 90.0% of COPD deaths occurred in middle and low-income countries in 2017. It further stated that countries like China and India alone accounted for approximately 66.0% of total COPD deaths. The regional market is therefore expected to strengthen such a high number of cases of respiratory diseases. An increase in healthcare expenses and awareness of patients is also expected to boost growth.
Global Nebulizer Market, By Type
Global Nebulizer Market, By Geography
The market research study on “Nebulizer Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Nebulizer market segments with market dynamics and their impact. The report also covers basic technology development policies.
The report provides an analysis of the latest industry trends from 2015 to 2026 in all sub-segment segments and forecasts revenue and volume growth on the global, the regional and country levels.
An overview of the market and its main concerns is a comprehensive analysis of the global nebulizer market. Market dynamics encompasses drivers, restraints and opportunities to simplify the behavior of the market. A thorough study into the products and geographic segments that would help to understand current market trends is presented in the Section on Market Segmentation. The analytics from Porter's Five Force could be useful in determining market profitability for strategists. The cost of the purchaser to switch a nebulizer product is low and the supplier has low negotiating power. Nebulizer products are less varied and the threat of new entrants is increasing. The threat of substitutes increases with low cost change for consumers and the accessibility of alternative therapies. Many competitors are present on the market and industrial rivalry is intense.
Key Players & Strategies
Koninklijke Philips N.V.; Omron Corporation; PARI Pharma; and Allied Healthcare Products, Inc. are prominent key players. Key players participate in the adoption of various strategies for strengthening their market position such as fusions and acquisitions, product launches and partnerships.
In June 2016, two SUN-101 pivotal Phase III trials were conducted with PARI Pharma eFlow technology. Sunovion aims to combine inhaler and nebulizer attributes into a single system, together with SUN-101 and eFlow technology.